Hakan Harputluoglu
Overview
Explore the profile of Hakan Harputluoglu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
464
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ozbay M, Harputluoglu H, Karaca M, Tekin O, Sendur M, Kaplan M, et al.
Cancers (Basel)
. 2024 Nov;
16(22).
PMID: 39594835
Background And Aims: During liver transplantation, hepatocellular carcinoma (HCC) recurrence remains a critical challenge for patient survival. Targeted therapies, such as sorafenib and regorafenib, have been utilized to manage relapsed...
2.
Siefker-Radtke A, Huddart R, Bilen M, Balar A, Castellano D, Sridhar S, et al.
Urol Oncol
. 2024 Oct;
PMID: 39477771
Background: In PIVOT-02, bempegaldesleukin (BEMPEG), a pegylated interleukin-2 cytokine prodrug, in combination with nivolumab (NIVO), a Programmed cell death protein 1 inhibitor, demonstrated the potential to provide additional benefits over...
3.
Yildirim M, Karadurmus N, Okten I, Turk H, Urakci Z, Arslan C, et al.
J Oncol Pharm Pract
. 2024 Apr;
:10781552241241004.
PMID: 38613329
Backgrounds And Objectives: Colorectal cancer is one of the leading causes of mortality both globally and in our country. In Turkey, we conducted a multicenter investigation into the effectiveness of...
4.
Olmez O, Bilici A, Er O, Bisgin A, Sevinc A, Akman T, et al.
Jpn J Clin Oncol
. 2024 Jan;
54(5):562-568.
PMID: 38271177
Objective: The objective of this multi-centre, real-world study was to examine the potential influence of comprehensive molecular profiling on the development of treatment decisions or adjustments for patients with advanced...
5.
Kutluk T, Sahin B, Kirazli M, Ahmed F, Aydin S, Yesil Cinkir H, et al.
JAMA Netw Open
. 2023 May;
6(5):e2312903.
PMID: 37219908
Importance: Cancer was a common noncommunicable disease in Syria before the present conflict and is now a major disease burden among 3.6 million Syrian refugees in Turkey. Data to inform...
6.
Hacioglu M, Erdogan B, Bardakci M, Algin E, Gulbagci B, Hacibekiroglu I, et al.
Head Neck
. 2023 Apr;
45(7):1643-1653.
PMID: 37084179
Background: Most of the studies on salivary gland cancers are limited for various reasons such as being single-center, small number of patients, including only major or minor SGCs, or only...
7.
Bilici A, Olmez O, Kaplan M, Oksuzoglu B, Sezer A, Karadurmus N, et al.
Acta Oncol
. 2023 Apr;
62(4):381-390.
PMID: 37083566
Aim: To investigate the pathological complete response (pCR) achieved after neoadjuvant therapy with versus without adding pertuzumab (P) to trastuzumab (H) plus neoadjuvant chemotherapy (NCT) in HER2+ breast cancer (BC)...
8.
Gulmez A, Harputluoglu H
J Gastrointest Cancer
. 2022 Feb;
54(1):11-19.
PMID: 35119620
Objective: Hepatocellular cancer (HCC) is an aggressive tumor with an increasing incidence in recent years. Life expectancy is limited, especially due to limited effective treatments and tumor biology. In this...
9.
Gulmez A, Dikilitas M, Elkiran E, Harputluoglu H
Cancer Treat Res Commun
. 2021 Apr;
27:100366.
PMID: 33812180
Sunitinib malate is a multitargeted oral tyrosine kinase inhibitor (TKI) which is used in treatment of metastatic renal cell carcinoma with side effects such as diarrhea, mucositis, asthenia and myelosuppression....
10.
Petrylak D, de Wit R, Chi K, Drakaki A, Sternberg C, Nishiyama H, et al.
Lancet Oncol
. 2019 Nov;
21(1):105-120.
PMID: 31753727
Background: Ramucirumab-an IgG1 vascular endothelial growth factor receptor 2 antagonist-plus docetaxel was previously reported to improve progression-free survival in platinum-refractory, advanced urothelial carcinoma. Here, we report the secondary endpoint of...